A trial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with reductions in quality of life, functional status, cardiac performance, and overall survival. 1, 2 In the past 14 years, left atrial catheter ablation to achieve pulmonary vein isolation (PVI) has emerged as an important nonpharmacological treatment option for maintaining sinus rhythm. 1 Unfortunately, despite an initial procedural success, a significant portion of patients experience an early recurrence of AF (ERAF) within the first few months after radiofrequency ablation. [3] [4] [5] [6] Although relatively common, the long-term clinical significance of these early recurrences remains controversial because a significant number of patients remain free of late recurrent arrhythmias despite ERAF. [3] [4] [5] [6] [7] [8] Although studies have retrospectively examined clinical variables associated with early and late arrhythmic recurrence after radiofrequency ablation, there is limited evidence regarding the prognostic significance of ERAF after cryoballoon ablation. 6, 9 Moreover, the effect of early reablation (ie, within the 3-month blanking period) in patients with early recurrences after cryoballoon ablation remains unknown.
The aims of the present study were to (1) determine the proportion of patients with AF recurrence within the first 3 months after cryoballoon-based PVI; (2) determine the long-term clinical significance of ERAF after cryoballoon-based PVI; (3) identify the clinical variables associated with early and late recurrence (LR) of AF after cryoballoon-based PVI, and (4) determine the effect of reablation on subsequent freedom from AF. February 2014 AAD drug therapy. The study population for this STOP AF substudy consists of all patients randomized to cryoballoon ablation (n=163).
Procedural Details
Written informed consent was obtained from each participant before study inclusion. The institutional review board at each participating center approved the study protocol.
All patients randomized to ablation underwent cryoballoon-based PVI. Preprocedural transesophageal echocardiography to exclude the presence of an atrial thrombus was performed before the ablation procedure. After transseptal access to the left atrium (LA) under fluoroscopic or intracardiac ultrasound guidance, patients were anticoagulated with intravenous heparin to maintain an activated clotting time >300 seconds. A multipolar catheter was placed in the coronary sinus, and a decapolar, circular mapping catheter was used for mapping and confirmation of PVI (acute procedural end point of entrance block). The standard transseptal sheath was upsized to a 14-French FlexCath Steerable Sheath (Medtronic CryoCath, Minneapolis, MN). Ablation was performed with 4-minute deliveries using the 23 or 28 mm Arctic Front catheter (Medtronic CryoCath). Repeat deliveries were at the discretion of the investigator. At the completion of the procedure, pacing was used to demonstrate entrance and, where assessable, exit block in each vein after a 30-minute waiting period. Cavotricuspid isthmus and focal ablation using the Freezor MAX Cardiac CryoAblation Catheter (Medtronic CryoCath) was undertaken in patients with previous clinical or inducible atrial flutter.
Postablation Follow-Up
All patients were discharged <2 days after the procedure. Anticoagulation with warfarin (target international normalized ratio, 2-3) was continued postprocedure for a minimum of 3 months. AAD therapy beyond the initial blanking period was strongly discouraged. 10 Patients were followed for 12 months after their cryoablation procedure. A clinical assessment and a 12-lead ECG were routinely performed in all patients at each of the 1-, 3-, 6-, 9-, and 12-month follow-up visits. Weekly transtelephonic monitoring (TTM) was used to detect asymptomatic recurrences (>90% compliance). In addition, patients also transmitted TTM recordings throughout the 12-month follow-up when experiencing arrhythmia symptoms. A 24-hour Holter recording was obtained at 6 and 12 months. All TTM and Holter results were read by an independent, blinded core laboratory. Recurrences of atrial arrhythmia lasting >30 seconds were based on 24-hour Holter, TTM, or ECG detection.
ERAF was defined as the presence of AF lasting >30 seconds within the first 3 months after the index ablation procedure. LR was defined as recurrence of AF of >30 seconds duration from 3 to 12 months after the index ablation procedure. Repeat ablation at any time was classified as a recurrence. No patient was lost to follow-up, and all underwent the required outpatient visits and monitoring.
Statistical Analysis
Continuous variables are expressed as mean±SD (or median [first and third quartiles; Q1, Q3]), and categorical variables are expressed as frequency and percentage. Comparisons between baseline characteristics were performed by independent Student t, Mann-Whitney rank-sum, Fisher exact, or χ 2 tests where appropriate. To analyze the association of baseline and procedural factors on ERAF and LR (in the total population and subpopulation with ERAF), Cox regression modeling was used. A multivariable model was used to estimate hazard ratios (HRs) for recurrence while controlling for patient demographic and clinical characteristics. The proportional hazards assumption was tested for each covariate using a model including a time-varying covariate for the covariate of interest. The covariate of early recurrence violated the proportional hazards assumption (P=0.0046 for the time-varying covariate). Therefore, to better assess the association of other covariates of interest with LR, a proportional hazards model stratified on early recurrence was used. For each of the 3 study outcomes, the multivariable Cox model considered covariates with univariable P values <0.20 for inclusion in the model. The final model was determined using a sequential backward and Table 1 forward stepwise selection with a P value of 0.05 for retention in the final model. Candidate variables for multivariable analyses included demographic information (age at randomization, sex), comorbidities (history of coronary artery disease, previous myocardial infarction, hypertension, diabetes mellitus, dyslipidemia, active tobacco use), medications (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; lipid-lowering drugs; previous flecainide, propafenone, or sotalol use), echocardiographic parameters (left atrial size, left ventricular ejection fraction), AF history (AF duration, past cardioversion, frequency of AF episodes, number of AADs failed), and procedural parameters (procedure duration, cryoablation time, number of cryoballoon applications, cryoballoon size, presence of nonstandard PV anatomy, focal catheter use, focal trigger ablation, incomplete PVI). At no point during the selection process did any model include >4 of the specified covariates. All tests were 2-sided. A P value <0.05 was considered statistically significant. All analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC).
. Characteristics of the Study Population and Index Ablation Procedure

Results
Patient Characteristics
Baseline characteristics and procedural details of the 163 patients who underwent cryoballoon ablation are presented in Table 1 .
Early Recurrence
Eighty-four patients (52%) had recurrent AF within the first 3 months of follow-up after the index cryoballoon ablation procedure. In the majority of patients, the first episode of ERAF occurred within the first month (72, 86% of those with ERAF) and particularly within the first 10 days (42, 50% of those with ERAF). After 1 month, the incidence decreased to 7% per month for postablation months 2 and 3 ( Figure 1 ).
Male sex was the only factor correlated with ERAF as identified by univariate (HR, 2.18; 95% confidence interval [CI], 1.03-4.61; P=0.04; Table 1 in the Data Supplement) and multivariable analysis (HR, 2.18; 95% CI, 1.03-4.61; P=0.04; Table 2 ). There was no relationship between ERAF and demographic variables (age and comorbidities), AF history (AF duration and frequency, concomitant atrial flutter, number of AADs failed, or past cardioversion), echocardiographic parameters (LA size, left ventricular ejection fraction), and procedural characteristics (procedure time, duration and number of cryoablation lesions, PV anatomy, 
Early Reablation
A subset of 30 patients (36%) experiencing early recurrence underwent reablation within the blanking period (early reablation). Characteristics of patients with or without early reablation are shown in Table 3 . No significant differences were observed with regard to patient demographics, AF history, echocardiographic parameters, and procedural characteristics. At repeat procedure, 62 of 115 PVs (54%) were noted to have been reconnected (4 of 4 left common PVs, 16 of 26 left inferior PVs, 18 of 26 left superior PVs, 13 of 30 right inferior PVs, 0 of 1 right middle PVs, and 11 of 30 right superior PVs). All PVs were reisolated at the repeat procedure, where a 23-mm cryoballoon was used in 45%, a 28-mm cryoballoon in 55%, and a focal cryocatheter in 29% of repeat procedures. Three patients undergoing reablation experienced phrenic nerve palsy (10%), which did not differ significantly from the rate of phrenic nerve palsy at index ablation (12%; 20 of 163).
Late Recurrence
During a follow-up of 12 months, 41 patients (25%) experienced recurrence of AF after the 3-month blanking period (ie, LR). LR was significantly related to ERAF (56% LR with ERAF versus 13% without ERAF; P<0.001; Table 2 in the Data Supplement). Excluding the group undergoing early reablation (30 patients), current tobacco use was significantly associated with LR on multivariable analysis stratified on early recurrence (adjusted HR, 3.17; 95% CI, 1.64-6.10; P<0.001; Table 2 ). Although increased LA size was associated with a greater risk of LR on univariate analysis (HR, 1.20; 95% CI, 1.05-1.38; P=0.007), it was not significant in the stratified multivariable model.
LR in Those With Early Recurrence
One-year freedom from recurrent AF was significantly lower in the ERAF group not undergoing early reablation (44%; 24 of 54 patients) when compared either to the group of patients who experienced ERAF and underwent early reablation (97%; 29 of 30 patients) or to the group of patients not experiencing ERAF (87%; 69 of 79 patients; P<0.0001; Figure 2 ).
Among all patients with early recurrence, the only significant factor associated with LR on multivariable analysis was current tobacco use (adjusted HR, 3.84; 95% CI, 1.82-8.11; Table 3 No statistically significant differences were noted between the 2 groups. ACE, angiotensin-converting enzyme; CTI, cavotricuspid isthmus; ERAF, early recurrence of atrial fibrillation (AF); HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; LCPV, left common pulmonary vein; PVI, pulmonary vein isolation; and RMPV, right middle pulmonary vein. 
. Characteristics of Subjects With Early Recurrence Who Did and Did Not Undergo Early Reablation
Discussion
Major Findings
Although recent studies have confirmed the predictive value of ERAF after radiofrequency catheter ablation, to the best of our knowledge, this is first time that early and late recurrence has been rigorously examined in a trial of cryoballoon ablation. A significant strength of the present study is the use of regular transtelephonic transmissions to detect asymptomatic recurrences, as well as the prospective ascertainment of arrhythmia end points. Through a prespecified analysis of the randomized multicenter STOP AF trial, we demonstrated the following key findings. (1) Approximately half of the patients will experience ERAF within the first 3 months after a cryoballoon-based PVI procedure.
(2) The majority (85%) of these recurrences occur within the first month. (3) ERAF after cryoballoon ablation is significantly correlated with LR, but nearly half of those with ERAF remain free of long-term recurrence. (4) Early reablation is associated with an excellent long-term freedom from recurrent AF (97% 1-year freedom from recurrent AF).
Incidence of Early and Late Recurrence
There is a theoretical rationale as to why the incidence and significance of ERAF may differ between radiofrequency and cryothermal ablation. 11, 12 Acute thermal injury effectuated by RF is characterized by coagulation and tissue necrosis and is followed by a marked inflammatory response within the atria, resulting in cellular dysfunction and enhanced arrhythmogenicity. These changes are thought to be mechanistically central to the occurrence of ERAF. In contrast, cryoablation results in the creation of dense, well-demarcated homogeneous lesions through a directed freezing process. [12] [13] [14] As a result, it can be postulated that cryothermal ablation should result in a lower rate of ERAF because of the relatively reduced inflammatory reaction. 15, 16 Interestingly, this was not observed in this prospective, randomized, multicenter study. Herein, we report a 52% incidence of ERAF <3 months of an index cryoballoon ablation procedure, which is consistent with nonrandomized observational studies after radiofrequency catheter ablation (16%-65%) as well as previous studies of cryoballoon ablation (44%). [3] [4] [5] [6] [7] [8] [9] Reassuringly, although ERAF was a relatively common occurrence after cryoballoon ablation, approximately half of these patients did not continue to have AF at longer-term follow-up, suggesting that transient periprocedural arrhythmogenicity is the predominant mechanism of ERAF in a subset of patients undergoing cryoballoon and RF ablation (44% with ERAF remained AF-free at 1 year, similar to the 46% rate reported after radiofrequency catheter ablation). [3] [4] [5] [6] [7] [8] Nevertheless, a significant proportion of patients undergoing repeat cryoballoon ablation had early reconnection (52% of PVs). As evidenced by the significantly improved 1-year freedom from recurrent AF in those undergoing early reablation, these reconnections are likely clinically relevant and responsible for later arrhymthmia recurrence.
Interestingly, clinical factors associated with more advanced disease (longer duration of AF, higher frequency of AF episodes, larger LA size), increased procedural complexity (longer procedure and ablation time, nonstandard PV anatomy, use of a focal catheter for touch-ups), or incomplete PVI were not associated with increased rates of recurrence. The strongest factor associated with long-term recurrence after ERAF was current tobacco use (HR, 3.84), which is postulated to facilitate arrhythmia recurrence through induction of inflammation, atrial fibrosis, or sympathetic neural stimulation. 17 Although we demonstrated an independent association between early reablation and improved long-term success, we cannot conclude that early reablation for ERAF after cryoablation is warranted in all. The nonrandomized decision to pursue reablation in the current study is subject to known Figure 2 . Kaplan-Meier curves depicting time to first recurrence of atrial fibrillation after a 3-month blanking period. Depicted are patients with early recurrence not undergoing reablation (blue line), patients without early recurrence (red line), and patients with early recurrence undergoing early reablation (green). The survival estimates at 6 and 12 months are 50% and 46% for patients with early recurrence not undergoing reablation, 98% and 87% for patients without early recurrence, and 97% and 97% for patients with early recurrence undergoing early reablation (logrank P<0.0001). ERAF indicates early recurrence of atrial fibrillation. and unknown confounders, and, therefore, the observed reduced long-term recurrence remains hypothesis-generating. Moreover, although early reablation was associated with improved long-term freedom from recurrent AF, nearly half of the patients with ERAF did not develop LR. Given the potential for late cure, risks of early reablation should be balanced against a conservative strategy.
Limitations
Although patients enrolled in the STOP AF trial had a relatively high arrhythmia burden of paroxysmal AF, our findings cannot be generalized to those with persistent AF or those undergoing ablation beyond isolated PVI. In addition, although the STOP AF trial is the largest randomized evaluation of cryoballoon ablation reported to date, the relatively small numbers have the potential to limit the ability to perform extensive modeling or adjusted analyses. Lastly, it is important to recall that the STOP AF trial included all patients from the beginning of an individual operator's experience with cryoballoon technology. It is possible that the initial lack of familiarity may have influenced the results of this study.
Conclusions
The results of this study confirm that ERAF is observed relatively frequently after cryoballoon-based PVI. Although ERAF was strongly associated with LR, and early reablation was associated with greater long-term freedom from recurrent AF, a significant proportion of patients with ERAF will not develop LR. Given the potential for late cure, the risks of early reablation should be balanced against a conservative strategy.
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